Table 1.
Patients’ characteristics.
| Variable | Category | Treated | Efficacy-Evaluable | ||
|---|---|---|---|---|---|
| (n = 20) | (n = 17) | ||||
| Age, Years; Median (Range) | 64 (43–78) | 63 (44–78) | |||
| Gender | Male | 9 | 45% | 7 | 41% |
| Female | 11 | 55% | 10 | 59% | |
| ECOG * | 0 | 6 | 30% | 5 | 29% |
| 1 | 13 | 65% | 12 | 71% | |
| MM isotype | IgG | 9 | 45% | 6 | 35% |
| IgA | 7 | 35% | 7 | 41% | |
| BJ | 4 | 20% | 4 | 24% | |
| ISS * | I | 6 | 33% | 6 | 40% |
| II | 6 | 33% | 5 | 33% | |
| III | 6 | 33% | 4 | 27% | |
| EMD | 0 | 0% | 0 | 0% | |
| No. of prior lines | 1 | 16 | 80% | 13 | 77% |
| 2 | 4 | 20% | 4 | 23% | |
| Prior ASCT | 16 | 80% | 14 | 82% | |
| Response at screening | VGPR | 11 | 55% | 8 | 47% |
| CR | 4 | 20% | 4 | 24% | |
| sCR | 5 | 25% | 5 | 29% | |
MM: multiple myeloma, BJ: Bence-Jones, ISS: International Staging System, EMD: extramedullary disease, ASCT: autologous stem cell transplantation, VGPR: very good partial response, CR: complete response, sCR: stringent complete response; * one and two cases with missing information.